ENOCHIAN BIOSCIENCES INC.
2080 Century Park East, Suite 906
Los Angeles, CA 90067
March 4, 2022
VIA EDGAR
United States Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Attn: Alan Campbell
| Re: | Enochian Biosciences Inc. | |
| Request for Acceleration of Registration Statement on Form S-3 | ||
| File No. 333-262673 |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Enochian Biosciences Inc., a Delaware corporation (the “Company”), hereby requests acceleration of the effectiveness of its Registration Statement on Form S-3 (File No. 333-262673), filed with the U.S. Securities and Exchange Commission on February 11, 2022, as amended, to 4:00PM ET on March 8, 2022 or as soon thereafter as practicable.
Please direct any questions or comments regarding this filing to Clayton Parker, Esq. at (305) 794-6293 of K&L Gates LLP, legal counsel to the Company.
| Sincerely, | |
| /s/ Mark Dybul | |
| Name: Mark Dybul Title: Chief Executive Officer |
